State Of Wyoming Avadel Pharmaceuticals PLC Transaction History

State Of Wyoming

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$12.55 - $17.22 $93,334 - $128,065	-7,437 Reduced 15.27%	41,267 $696,000
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $66,544 - $100,714	6,903 Added 16.51%	48,704 $687,000
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $70,472 - $109,403	6,842 Added 19.57%	41,801 $430,000
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $68,314 - $132,762	8,056 Added 29.94%	34,959 $576,000
Q1 2023 May 12, 2023	SELL	$6.41 - $9.95 $14,146 - $21,959	-2,207 Reduced 7.58%	26,903 $246,000
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $20,085 - $40,010	4,001 Added 15.93%	29,110 $208,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $30,855 - $87,763	12,006 Added 91.63%	25,109 $126,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $14,020 - $91,065	13,103 New	13,103 $32,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.